Health Condition 1: I820- Budd-Chiari syndrome
Conditions
Interventions
Intervention1: Genotyping arm: Pharmacogenetic analysis for mutations in VKORC1 and CYP2C9 gene and subsequent warfarin therapy
Control Intervention1: Non-Genotyping arm: Usual standard of care and wa
Sponsors
Dr Akash Shukla
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who are newly diagnosed for Budd Chiari and are warfarin naive 2. Aged 18 years to 60 years of either gender 3. Patients willing to give voluntarily written informed consent 4. Patient willing to comply with protocol requirements
Exclusion criteria
Exclusion criteria: 1. Genotype (CYP2C9 and VKORC1) known to participant from prior testing or available in medical record. 2. Pregnancy or lactation 3. Any other clinical condition as per physicianâ??s judgment which compromises safety of the participant or credibility of the data. 4. Patients with contraindications to warfarin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proportion of patients with bleeding in the genotyping group and standard group.Timepoint: every 3 months for a period of 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Thrombosis of stent / hepatic veinTimepoint: 24 months;Incremental cost effectiveness ratioTimepoint: 24 months;Number of major and minor bleedsTimepoint: 24 months;number of times a patient is in therapeutic range (TR)Timepoint: over a period of 24 months | — |
Countries
India
Contacts
Public ContactDr Akash Shukla
Lokmanya Tilak Municipal Medical College & General Hospital
Outcome results
None listed